People · Operator
Named in public records as an officer, director or promoter · active 2010–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| VelosBio Inc. | — | Biotechnology | Series D+ | $210.5M | $5.6B | 2018 |
| Oncternal Therapeutics, Inc. | — | Biotechnology | Series C | $186.1M | $222.6M | 2014 |
| Precision IBD, Inc. | — | Biotechnology | Series C | $111.8M | $1.8B | 2017 |
| Exagen Diagnostics Inc | — | Biotechnology | Series B | $88.5M | $261.4M | 2010 |
| Alastin Skincare, Inc. | — | Biotechnology | Series A | $31.4M | $357.2M | 2015 |
| Rebalance Health, Inc. | — | Biotechnology | Series A | $21.7M | $58.8M | 2020 |
| Kalyra Pharmaceuticals, Inc. | — | Biotechnology | Series A | $11.4M | $223.5M | 2013 |
| Evoke Pharma Inc | — | Biotechnology | Series A | $6.0M | $216.9M | 2010 |
| Selexagen Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $1.1M | $33.0M | 2010 |
Scott L. Glenn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Scott L. Glenn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Cam L. Garner | 4 | 11 |
| Lauren G. Otsuki | 3 | 3 |
| William R. LaRue | 2 | 3 |
| David Johnson | 1 | 35 |
| David F Hale | 1 | 16 |
| David Blivin | 1 | 14 |
| Dinesh Patel | 1 | 13 |
| Brian Birk | 1 | 8 |
| Alan Colowick | 1 | 7 |
| Cam Gallagher | 1 | 7 |
| David B. Johnson | 1 | 6 |
| James L.L. Tullis | 1 | 6 |
| Gerald T. Proehl | 1 | 5 |
| MIN CUI | 1 | 5 |
| Waneta C. Tuttle | 1 | 4 |
| Lauren Otsuki | 1 | 4 |
| Scott Glenn | 1 | 4 |
| Mark Chin | 1 | 4 |
| Jayson Punwani | 1 | 3 |
| Lisa Davis | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.